Karuna Therapeutics, Inc. Stock News

Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Karuna Therapeutics ( KRTX – Research Report ) today and set a price target of $120.00 . The company’s shares closed last Monday at

Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl

Stocks plunge into a bear market as the viral outbreak threatens to devastate the economy. Healthcare has performed relatively better than the broader market wh

Fear mounts as investors brace for a viral outbreak in the US. Volatility to remain high as Covid-19 virus remains an unknown threat. Impact on earnings outlook

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote

AbbVie (NYSE:ABBV) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket.Alkermes plc (NASDAQ:ALKS) initiated with Neutral rating and $19 (fl

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote

Healthcare is entering a period where election cycle impact will grow. The Medicare for All healthcare plan will begin to get factored based on the success of t

BXCL501 is a major driving force for BioXcel Therapeutics. The company is targeting a billion-dollar opportunity in agitation space. Investors should consider t

Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo Wells Fargo RVNC AMPH EBS BHC AGN EOLS JAZZ KRTX PRGO TEVA MNK OSMT

Systematic or Quantitative Investing continues to be a bigger part of the market as it delivers stronger market-beating returns fairly consistently. Experts oft

Insiders invest in Salesforce.com, Lamb Weston, Karuna Therapeutics and Compass Diversified Holdings Continue reading...

Aptose Biosciences (APS CN) initiated with Overweight rating at Piper Sandler. Shares up 2% premarket in U.S. (NASDAQ:APTO).BioDelivery Sciences (NASDAQ:BDSI) initiated with Overweight rating and $9

Biotechs closed out 2019 on a strong note, with the fourth quarter providing the longest sustained rally of the entire year. Favorable regulatory shifting, a ti

The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK